BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25845918)

  • 1. Abdominal pain endpoints currently recommended by the FDA and EMA for adult patients with irritable bowel syndrome may not be reliable in children.
    Saps M; Lavigne JV
    Neurogastroenterol Motil; 2015 Jun; 27(6):849-55. PubMed ID: 25845918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of abdominal pain through global outcomes and recent FDA recommendations in children: are we ready for change?
    Mohammad S; Di Lorenzo C; Youssef NN; Miranda A; Nurko S; Hyman P; Saps M
    J Pediatr Gastroenterol Nutr; 2014 Jan; 58(1):46-50. PubMed ID: 23857339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders.
    Saps M; Youssef N; Miranda A; Nurko S; Hyman P; Cocjin J; Di Lorenzo C
    Gastroenterology; 2009 Oct; 137(4):1261-9. PubMed ID: 19596010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of screening electrocardiogram before the initiation of amitriptyline therapy in children with functional abdominal pain.
    Patra KP; Sankararaman S; Jackson R; Hussain SZ
    Clin Pediatr (Phila); 2012 Sep; 51(9):848-51. PubMed ID: 22619399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
    Corsetti M; Tack J
    Neurogastroenterol Motil; 2013 Jun; 25(6):453-7. PubMed ID: 23672677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents.
    Bahar RJ; Collins BS; Steinmetz B; Ament ME
    J Pediatr; 2008 May; 152(5):685-9. PubMed ID: 18410774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The power of placebo in pediatric functional gastrointestinal disease.
    Benninga MA; Mayer EA
    Gastroenterology; 2009 Oct; 137(4):1207-10. PubMed ID: 19717127
    [No Abstract]   [Full Text] [Related]  

  • 8. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial.
    Pace F; Maurano A; Ciacci C; Savarino V; Attili A; Iaquinto G; Magni E; Porro GB
    Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):155-62. PubMed ID: 20391952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome.
    Vahedi H; Merat S; Momtahen S; Kazzazi AS; Ghaffari N; Olfati G; Malekzadeh R
    Aliment Pharmacol Ther; 2008 Apr; 27(8):678-84. PubMed ID: 18248658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of alverina citrate and simethicone combination in abdominal pain and discomfort of irritable bowel syndrome].
    Wittmann T; Paradovsky L; Ducrotte P; Bueno L; Andro-Delestrain MC
    Eksp Klin Gastroenterol; 2011; (3):60-7. PubMed ID: 21698811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.
    Wittmann T; Paradowski L; Ducrotté P; Bueno L; Andro Delestrain MC
    Aliment Pharmacol Ther; 2010 Mar; 31(6):615-24. PubMed ID: 20003095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
    Chang FY; Lu CL; Chen CY; Luo JC
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.
    Macdougall JE; Johnston JM; Lavins BJ; Nelson LM; Williams VS; Carson RT; Shiff SJ; Shi K; Kurtz CB; Baird MJ; Currie MG; Lembo AJ
    Neurogastroenterol Motil; 2013 Jun; 25(6):481-6. PubMed ID: 23384406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome.
    Drossman DA; Danilewitz M; Naesdal J; Hwang C; Adler J; Silberg DG
    Am J Gastroenterol; 2008 Oct; 103(10):2562-9. PubMed ID: 18775020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amitriptyline for the treatment of irritable bowel syndrome.
    van Leeuwen Y; Rafiee M
    J Pediatr; 2008 Dec; 153(6):872; author reply 872-4. PubMed ID: 19014828
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.
    Chapman RW; Stanghellini V; Geraint M; Halphen M
    Am J Gastroenterol; 2013 Sep; 108(9):1508-15. PubMed ID: 23835436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Clinical Trial.
    Nurko S; Saps M; Kossowsky J; Zion SR; Di Lorenzo C; Vaz K; Hawthorne K; Wu R; Ciciora S; Rosen JM; Kaptchuk TJ; Kelley JM
    JAMA Pediatr; 2022 Apr; 176(4):349-356. PubMed ID: 35099543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study.
    Guandalini S; Magazzù G; Chiaro A; La Balestra V; Di Nardo G; Gopalan S; Sibal A; Romano C; Canani RB; Lionetti P; Setty M
    J Pediatr Gastroenterol Nutr; 2010 Jul; 51(1):24-30. PubMed ID: 20453678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.